desfuroylceftiofur

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

desfuroylceftiofur: metabolite of ceftiofur; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	71433827
MeSH ID	M0174863

Synonyms (1)

Synonym
desfuroylceftiofur

Research Excerpts

Pharmacokinetics

Excerpt	Reference	Relevance
" Cmax values were similar in all calves, and were no higher in younger calves than in older calves."	( Effects of age on the pharmacokinetics of single dose ceftiofur sodium administered intramuscularly or intravenously to cattle. Brown, SA; Chester, ST; Robb, EJ, 1996)	0.29
" The harmonic mean ± pseudo-SD terminal half-life of ceftiofur was 29."	( Pharmacokinetics of long-acting ceftiofur crystalline-free acid in helmeted guineafowl (Numida meleagris) after a single intramuscular injection. Adkesson, MJ; Cox, SK; Gamble, KC; Langan, JN; Wojick, KB, 2011)	0.37
"To determine the pharmacokinetic properties of 1 IM injection of ceftiofur crystalline-free acid (CCFA) in American black ducks (Anas rubripes)."	( Pharmacokinetics of a single intramuscular injection of ceftiofur crystalline-free acid in American black ducks (Anas rubripes). Boedeker, NC; Byrne, BA; Hope, KL; Lynch, W; Murray, S; Padilla, LR; Tell, LA; Ware, LH; Wetzlich, SE, 2012)	0.38
"1 μg/mL, time to maximum plasma concentration observed was 24 hours, terminal phase half-life was 32."	( Pharmacokinetics of a single intramuscular injection of ceftiofur crystalline-free acid in American black ducks (Anas rubripes). Boedeker, NC; Byrne, BA; Hope, KL; Lynch, W; Murray, S; Padilla, LR; Tell, LA; Ware, LH; Wetzlich, SE, 2012)	0.38
" The terminal elimination half-life associated with the slope of the terminal phase had a harmonic mean ± pseudo-SD of 83."	( Pharmacokinetics of a long-acting ceftiofur crystalline-free acid formulation in Asian elephants (Elephas maximus). Adkesson, MJ; Allender, MC; Junge, RE; Martín-Jiménez, T, 2012)	0.38
"In a preliminary experiment, doses of 15 and 30 mg/kg, SC, were compared in 2 animals, and 30 mg/kg resulted in a more desirable pharmacokinetic profile."	( Pharmacokinetics of subcutaneous versus intramuscular administration of ceftiofur crystalline-free acid to bearded dragons (Pogona vitticeps). Churgin, SM; Cox, SK; Musgrave, KE; Sladky, KK, 2014)	0.4
"Administration of ceftiofur sodium via nebulisation has been recommended for the treatment of bronchopneumonia in horses, despite the lack of pharmacokinetic and safety data."	( Pulmonary pharmacokinetics of desfuroylceftiofur acetamide after nebulisation or intramuscular administration of ceftiofur sodium to weanling foals. Berghaus, LJ; Fultz, L; Giguère, S; Grover, GS; Merritt, DA, 2015)	0.42
"The objective of this study was to compare the plasma pharmacokinetic profile of ceftiofur crystalline-free acid (CCFA) and ceftiofur sodium in neonatal calves between 4 and 6 days of age."	( Comparative plasma pharmacokinetics of ceftiofur sodium and ceftiofur crystalline-free acid in neonatal calves. Caldwell, M; Cox, S; Credille, BC; Hines, M; Woodrow, JS, 2016)	0.43

Dosage Studied

Excerpt	Relevance	Reference
" In conclusion, with the exception of the staphylococci, both XNL and DXNL were highly active against the organisms tested, with MICs for both compounds several fold lower than plasma levels achieved during dosing of XNL."	( In vitro activity of ceftiofur and its primary metabolite, desfuroylceftiofur, against organisms of veterinary importance. Salmon, SA; Watts, JL; Yancey, RJ, 1996)	0.29
" Group 1 calves were dosed at 7 days of age and at 1 and 3 months of age; group 2 calves were dosed at 6 and 9 months of age."	( Effects of age on the pharmacokinetics of single dose ceftiofur sodium administered intramuscularly or intravenously to cattle. Brown, SA; Chester, ST; Robb, EJ, 1996)	0.29
"On the basis of the time that CFAE concentrations were higher than the target plasma concentration, a dosing interval of 3 days can be recommended for future multidose CCFA studies."	( Pharmacokinetics of a single intramuscular injection of ceftiofur crystalline-free acid in American black ducks (Anas rubripes). Boedeker, NC; Byrne, BA; Hope, KL; Lynch, W; Murray, S; Padilla, LR; Tell, LA; Ware, LH; Wetzlich, SE, 2012)	0.38
" Dosing recommendations will depend on the mean inhibitory concentration of ceftiofur for each bacterial pathogen."	( Pharmacokinetics of a long-acting ceftiofur crystalline-free acid formulation in Asian elephants (Elephas maximus). Adkesson, MJ; Allender, MC; Junge, RE; Martín-Jiménez, T, 2012)	0.38
" There are currently no data to guide an appropriate dosing interval when a longer treatment regimen is warranted."	( Plasma and pulmonary pharmacokinetics of desfuroylceftiofur acetamide after weekly administration of ceftiofur crystalline free acid to adult horses. Berghaus, LJ; Davis, JL; Fultz, L; Giguère, S, 2014)	0.4
" Concentrations of DCA in plasma and PELF remained in the therapeutic range for the entire dosing interval."	( Plasma and pulmonary pharmacokinetics of desfuroylceftiofur acetamide after weekly administration of ceftiofur crystalline free acid to adult horses. Berghaus, LJ; Davis, JL; Fultz, L; Giguère, S, 2014)	0.4
" Incurred tissue samples were obtained from dosed animals and analyzed to evaluate the utility of the method."	( Determination of ceftiofur metabolite desfuroylceftiofur cysteine disulfide in bovine tissues using liquid chromatography-tandem mass spectrometry as a surrogate marker residue for ceftiofur. Chattopadhaya, C; Chiesa, OA; Feng, S; Girard, L; Kijak, P; Lancaster, V; Li, H; Sklenka, S; Smith, EA, 2014)	0.4

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	8 (30.77)	18.2507
2000's	2 (7.69)	29.6817
2010's	15 (57.69)	24.3611
2020's	1 (3.85)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (10.71%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	25 (89.29%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
chloramphenicol Amphenicol: Chloramphenicol and its derivatives.	2.11	1	0	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
cloxacillin Cloxacillin: A semi-synthetic antibiotic that is a chlorinated derivative of OXACILLIN.. cloxacillin : A semisynthetic penicillin antibiotic carrying a 3-(2-chlorophenyl)-5-methylisoxazole-4-carboxamido group at position 6.	2.04	1	0	penicillin allergen; penicillin; semisynthetic derivative	antibacterial agent; antibacterial drug
ampicillin Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.	7.52	2	0	beta-lactam antibiotic; penicillin allergen; penicillin	antibacterial drug
streptomycin [no description available]	2.11	1	0	antibiotic antifungal drug; antibiotic fungicide; streptomycins	antibacterial drug; antifungal agrochemical; antimicrobial agent; antimicrobial drug; bacterial metabolite; protein synthesis inhibitor
amoxicillin Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.	2.04	1	0	penicillin allergen; penicillin	antibacterial drug
cephalosporin c cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.	6.94	26	3	cephalosporin	fungal metabolite
beta-lactams 2-azetidinone: structure in first source. azetidin-2-one : An unsubstituted beta-lactam compound.. beta-lactam : A lactam in which the amide bond is contained within a four-membered ring, which includes the amide nitrogen and the carbonyl carbon.	2.04	1	0	beta-lactam antibiotic allergen; beta-lactam
cystine [no description available]	1.99	1	0
clavulanic acid Clavulanic Acid: A beta-lactam antibiotic produced by the actinobacterium Streptomyces clavuligerus. It is a suicide inhibitor of bacterial beta-lactamase enzymes. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase.. clavulanate : The conjugate base of clavulanic acid.. clavulanic acid : Antibiotic isolated from Streptomyces clavuligerus. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes.	7.41	1	0	oxapenam	antibacterial drug; anxiolytic drug; bacterial metabolite; EC 3.5.2.6 (beta-lactamase) inhibitor
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	2.49	2	0	cysteinium	fundamental metabolite
nitrocefin nitrocefin: chromogenic cephalosporin used for detection of beta-lactamase activity; Cefinase is name for nitrocefin on paper disc; RN given refers to (6R-(3(E),6 alpha,7 beta))-isomer; structure for mono-Na salt in second source	7.41	1	0
ceftiofur ceftiofur: structure in first source	6.87	24	3

Condition	Relationship Strength	Studies
Diathesis [description not available]	2.11	1
E coli Infections [description not available]	2.11	1
Swine Diseases Diseases of domestic swine and of the wild boar of the genus Sus.	2.11	1
Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI.	2.11	1
Placenta Diseases Pathological processes or abnormal functions of the PLACENTA.	2.08	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.08	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.42	2
Bacterial Disease [description not available]	1.99	1
Bacterial Infections Infections by bacteria, general or unspecified.	1.99	1
Bovine Diseases [description not available]	1.99	1
Infections, Pasteurella [description not available]	1.99	1
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	1.99	1

chemdatabank.com